BackIllumina Overview
Illumina Inc

Illumina Target Price

Analysts' average 12-month price target for Illumina is $240.

Get informed when a big investor buys or sells

+ Follow

Share Price

$212.93

Average Target Price

$241.0713.2% upside

15 analysts in the last 4 months

High: $305 | Low: $160

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-23Stephens$27529.2% upsideOpen
2026-10-19Canaccord Genuity$30040.9% upsideOpen
2026-10-07Barclays$2006.1% downsideOpen
2026-10-01GuggenheimSubbu Nambi$30543.2% upsideOpen
2026-09-29Leerink Partners$30040.9% upsideOpen
2026-09-28Piper SandlerDavid Westenberg$30543.2% upsideOpen
2026-09-09UBS$26022.1% upsideOpen
2026-09-03Argus Research$23510.4% upsideOpen
2026-08-03Canaccord Genuity$2053.7% downsideOpen
2026-07-31RBC Capital$2308% upsideOpen
2026-07-31Bernstein$2151% upsideOpen
2026-07-31Guggenheim$2266.1% upsideOpen
2026-07-31Barclays$16024.9% downsideOpen
2026-07-17Leerink PartnersPuneet Souda$2101.4% downsideOpen
2026-07-14Canaccord GenuityKyle Mikson$19010.8% downsideOpen
2026-06-29Guggenheim$2006.1% downsideOpen
2026-06-26Bernstein$18513.1% downsideOpen
2026-06-01Guggenheim$18015.5% downsideOpen
2026-05-14RBC Capital$17020.2% downsideOpen
2026-05-14DaiwaIllumina to Outperform$15527.2% downsideOpen
2026-05-01Canaccord Genuity$14034.3% downsideOpen
2026-05-01Barclays$12242.7% downsideOpen
2026-02-09Piper Sandler$17020.2% downsideOpen
2026-02-06Robert W. BairdCatherine Ramsey Schulte$13735.7% downsideOpen
2026-02-06UBS$13536.6% downsideOpen
2026-02-06Evercore ISI$15029.6% downsideOpen
2026-01-26GuggenheimSubbu Nambi$17020.2% downsideOpen
2026-01-26Canaccord Genuity$15029.6% downsideOpen
2026-01-20Stifel NicolausDaniel Arias$15527.2% downsideOpen
2026-01-05Evercore ISIVijay Kumar$15527.2% downsideOpen
2026-01-05Guggenheim$14432.4% downsideOpen
2025-12-15Barclays$11048.3% downsideOpen
2025-10-31Evercore ISIVijay Kumar$14233.3% downsideOpen
2025-10-31Robert W. Baird$10948.8% downsideOpen
2025-10-31UBS$12043.6% downsideOpen
2025-10-31Canaccord Genuity$11247.4% downsideOpen
2025-10-31BarclaysLuke Sergott$10053% downsideOpen
2025-10-24Robert W. Baird$10550.7% downsideOpen
2025-10-02Barclays$9555.4% downsideOpen
2025-09-02RBC Capital$12441.8% downsideOpen
2025-08-04Morgan Stanley$10550.7% downsideOpen
2025-08-04Stephens$11048.3% downsideOpen
2025-06-24BarclaysLuke Sergott$8560.1% downsideOpen
2025-05-15Piper SandlerDavid Westenberg$18513.1% downsideOpen
2025-03-11Canaccord Genuity$11546% downsideOpen
2025-03-05Robert W. Baird$9057.7% downsideOpen
2025-02-28National Bank$10053% downsideOpen
2025-02-28HSBC$10053% downsideOpen
2025-02-03BarclaysLuke Sergott$13038.9% downsideOpen
2025-01-10BernsteinEve Burstein$14034.3% downsideOpen

Illumina (ILMN) FAQ

The latest target price for ILMN is $240. Investors often review this figure alongside Illumina's historical trend and sector peers before judging valuation or financial health.

Illumina trades near $212.93 while the consensus target sits at $240 (13.2% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting ILMN's target price ($240), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Illumina's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.